Novimmune Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
MRUS | C | Merus N.V. | -0.83 | |
TAK | F | Takeda Pharmaceutical Company Limited | -0.15 |
Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
PPH | B | Market Vectors Pharmaceutical ETF | 4.03 | |
SBIO | D | ALPS Medical Breakthroughs ETF | 1.65 | |
PTH | D | Invesco DWA Healthcare Momentum ETF | 1.53 | |
BBC | D | Virtus LifeSci Biotech Clinical Trials ETF | 1.39 | |
CNCR | D | Loncar Cancer Immunotherapy ETF | 1.33 |
Compare ETFs
- Novimmune
Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases. The company was founded in 1998.Novimmune has six publicly disclosed drug in their pipeline:
NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014 and phase II trials are expected to begin in early 2017.
NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively.
NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis. A phase II/III trial began in 2013 and is ongoing. The FDA awarded breakthrough status to the drug in 2016.
NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases.
NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers.
NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors.No drugs have been approved as of yet.
Popular Now
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Featured Articles